Non-invasive Glioma Characterization Through Molecular Imaging
NCT: NCT03684109 · RECRUITING
NCT IDNCT03684109
StatusRECRUITING
Start Date2019-01-25
Completion2027-01-31
Brief Summary
MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.
Frequently Asked Questions
What is Non-invasive Glioma Characterization Through Molecular Imaging?
Non-invasive Glioma Characterization Through Molecular Imaging is a clinical trial registered under NCT03684109. Current status: RECRUITING.
What is the status of NCT03684109?
The current status of NCT03684109 (Non-invasive Glioma Characterization Through Molecular Imaging) is: RECRUITING.
When did Non-invasive Glioma Characterization Through Molecular Imaging start?
Non-invasive Glioma Characterization Through Molecular Imaging started on 2019-01-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.